Kamala Harris Makes Up Fictional Agency On The Spot

The “Federal Drug Administration” did not authorize the abortion medication mifepristone 20 years ago, as Vice President Kamala Harris incorrectly stated last week.

The FDA is the proper organization but does not represent the “Federal Drug Administration.”

The FDA is the “Food and Drug Administration.” 

On Friday night’s episode of Noticias Telemundo with Vanessa Hauc, Vice President Harris discussed abortion and the current political climate in the United States.

Harris said the state has no business directing a private citizen on how to treat her body. (Unless it’s vaccination.)

The vice president then discussed the abortion medication mifepristone, which was authorized by the FDA in 2000.

According to Harris, politicians found a court they thought would be helpful to them” to remove a medication from the market that the FDA cleared 20 years ago. She then invited everybody with a medicine cabinet to look at any prescription medications they might have.

Harris claimed that the FDA had authorized the use of any medication recommended, whether it be for pain relief or to increase the patient’s lifespan.

She said, arguably, what is happening with mifepristone could happen to all the other drugs in your medicine cabinet.

While the lawsuit goes through the lower federal courts, the Supreme Court ruled on the same day that the interview with Harris aired that unrestricted access to the abortion pill could remain.

U.S. District Judge Matthew J. Kacsmaryk, appointed by Trump, issued a judgment that agreed with pro-life groups by blocking the FDA’s clearance of mifepristone. This case ultimately made its way to the Supreme Court.

The 5th U.S. Circuit of Appeals reversed a portion of Kacsmaryk’s order, but the appeals court upheld limits on how long the medicine may be prescribed (7 weeks instead of 10) and ruled that it could not be delivered by mail.

The Department of Justice contended that maintaining the ban on the drug would lead to anarchy.

Complicating matters further, in response to a separate lawsuit launched by 17 Democrat-led states and the District of Columbia, a federal court in Washington ordered the FDA to protect access to mifepristone under the current guidelines.